As I have expressed yesterday, companies releasing positive announcement/s before the FOMC meeting would have to face the risk of the resulting SP climb momentum erased to some extent if the signal from the FED is one that disappoints the market. In the midst of indiscriminate selling due to fear, companies releasing good news in the effort to stop it would be like them trying to extinguish a forest fire with an eye dropper, that is it is a waste of eye dropper and good news. Now that the market knows a little bit more of what to come from today's meeting, I think the time is riper for Moderna to start releasing good news again. But if I were them, I would still wait just a little bit. GL all. ps: I am a stock enthusiast with a science background sharing my thoughts but I am not a financial expert. Please do your own research. GLTA.
D
Shorts, prepare to pay the piper starting tomorrow.
G
Moderna Inc. has started testing in people a version of its Covid-19 vaccine modified to target the Omicron variant of the coronavirus, in case such a shot is needed to bolster protection.
Moderna said Wednesday the first clinical-trial volunteer received a dose of its Omicron-specific booster shot, code-named mRNA-1273.529.
The Cambridge, Mass., company didn't provide a timetable for when results might be available, but its previous vaccine studies evaluating immune responses have generated preliminary results within about two months.
The start of Moderna's testing, shortly after Pfizer Inc. and BioNTech SE began a similar study, brings vaccine makers and government officials closer to a thorny decision about whether to roll out an Omicron-specific vaccine.
While vaccine-company executives have said they think Omicron-specific boosters will be needed, U.S. government officials have been more cautious, saying current vaccines with boosters might be sufficient to protect against severe disease, even if they don't stop infections.
Also, the current Omicron surge may fade by the time study results are known for the Omicron-specific boosters.
The Omicron variant now spreading around the U.S. and world has mutations that make it less susceptible to immune- system antibodies induced by Moderna's original vaccine, mRNA-1273, also known as Spikevax.
Moderna designed an Omicron-specific vaccine soon after the variant was identified in November.
Since then, Moderna and other researchers have run tests finding that the authorized booster shot of its original vaccine can restore protection against the Omicron strain.
"Nonetheless, given the long-term threat demonstrated by Omicron's immune escape, we are advancing our Omicron- specific variant vaccine booster candidate," said Moderna Chief Executive Stéphane Bancel.
Authorities may determine the Omicron-specific vaccine is warranted if the effectiveness of the original vaccine combined with a booster wanes significantly.
The booster is being tested in an extension of an ongoing middle-stage, or Phase 2, clinical trial that Moderna had previously started to test booster shots. Moderna is conducting the study at 24 locations in the U.S.
In one new portion of the trial, researchers will give a single booster dose of the Omicron-specific vaccine to about 300 adults 18 and older, at least six months after receiving the two-dose primary series of Moderna's original vaccine.
A second group of 300 subjects, who have already received the third dose of Moderna's original vaccine, will receive a booster dose of the Omicron-targeted shot at least three months after getting the original booster dose.
Researchers will track the safety of the Omicron-specific booster shot, and whether it induces immune responses that are likely to be protective against disease caused by the variant.
Separately, a new analysis using blood samples from vaccinated people found that a booster dose of Moderna's vaccine increased neutralizing antibodies against Omicron.
The antibody levels declined, but were still detectable six months after a booster shot, according to the analysis.
The analysis, conducted by researchers from Moderna, the federal government and academic labs, was published online Wednesday by the New England Journal of Medicine.
R
The speed and scope of the omicron wave sweeping the world means one thing is nearly certain, more mutant variants are coming. Moderna needs a new vaccine, current booster is only 5% effective on BA.2 Stealth Omicron sub - variant. Pfizer testing a new omicron vaccine. Medicago’s bid to become the first COVID-19 vaccine maker in Canada to get a product to market for use either as a booster shot or as a first vaccine in places that remain critically unprotected from the disease.
e
Where’s JON Lol
C
Breaking Information Omicron BA.2 Evades mRNA Vaccine. As Omicron continues to spread rapidly across the world, experts have warned about a more transmissible sub-strain of the new variant dubbed as 'Stealth Omicron'. The new sub-strain has been dubbed as 'stealth' given that it is able to escape detection even in RT-PCR tests.
BA.2 'stealth' Omicron COVID-19 variant: What in known - Pfizer trying to stop it with new vaccine. This version of the coronavirus, which scientists call BA.2, is widely considered stealthier than the original version of Omicron and mRNA vaccine not stopping it. Scientists and health officials around the world are keeping their eyes on a descendant of the Omicron variant that has been found in at least 48 countries, including Australia.
Plant-Based COVID-19 Vaccine. Medicago is privately owned by a subsidiary of Mitsubishi Tanabe Pharma (67%) and Phillip Morris International (33%). In December 2020, Takashi Nagao became President and Chief Executive Officer, replacing Dr. Bruce D. Clark.
Medicago’s bid to become the first COVID-19 vaccine maker in Canada to get a product to market for use either as a booster shot or as a first vaccine in places that remain critically unprotected from the disease.
“When we got the results the first reaction was, thank God it works. We were absolutely delighted,” said Brian Ward, Medicago’s medical officer and a professor of medicine and microbiology at McGill University in Montreal. Earlier-stage trials with hundreds of participants suggested the vaccine was safe and that it generated an immune response, but it had to be tested with a much larger group of people in order for researchers to measure its efficacy.
Dr. Ward said the results should not be compared directly with figures released last year by Pfizer-BioNTech and Moderna during the clinical trials for their vaccines. Both showed greater than 90-per-cent efficacy. But those trials were conducted before COVID-19 variants of concern were widespread. The variants have presented vaccines with a somewhat different pathogen than the one they were designed to fight.
“In the variant world, 70 to 75 per cent is a really good vaccine,” Dr. Ward said.
The randomized controlled Phase 3 trial, which got under way in March, involved 24,000 participants. More than two-thirds were located in Brazil and Argentina, and the rest were in the U.S., Mexico, Canada and Britain. Half of those who participated received the Medicago vaccine in two doses separated by 21 days. The other half received a placebo.
Overall, the results showed the vaccine to have 71-per-cent efficacy against all variants that were circulating in the study populations at the time. Its efficacy against the Delta variant, which is currently dominant in Canada, was 75.3 per cent. The efficacy was 88.6 per cent against the Gamma variant. The Omicron variant, now a focus of global concern, had not yet made its appearance when the trial was under way. Information about the vaccine’s efficacy against the new variant may emerge as data continue to accumulate.
P
If you love cancer meds and chemotherapy then I can see your sentiment against Moderna. But for those of us who have seen cancer up close and personal we know better. My hopes are that the cancer program is successful and we find a better way to heal. Good luck to all.
X
Lets hope this new vaccine also combats the new omicron stealth variants
K
Whatever happened to all those on this sight who were Bullish and long on Moderna? Are there any of us left?
J
Now everybody loves Moderna
L
In case you’re not dizzy yet: “Recently, Brookline Capital upped its price target on Moderna from $475 to $506, which implies upside of 202%, based on where it closed on Jan. 20.”
D
Shorts, Please assume the special Yoga supine position of “bend over to pick up a bar of soap” and “thank you may i please have another” yoga stance tomorrow and into the coming months ahead.
Your time of fun is up and MRNA will be rocketing 🚀 back UP and UP in the very near term.
t
Remember the Fundamentals will drive Moderna back to $500 soon.
$18b in the bank $21b in backlog $32b 2022 est. revenue $20b 2022 EBIT $93 EOY Per Share Cash on Hand Forward PE 3
C
Omicron evades Moderna vaccine too, study suggests, but boosters help only about 10% variant. But getting a booster pumps the protection back up just a little again, new research suggests.
OK now we're back in gear. Should be some good momentum over the next few days as it becomes clear that omicron is just the beginning of new variants and as shorts cover.
M
Medicago COVID-19 Pant Based Vaccine : SUPERHERO VLPS: Plant-based virus-like particles (VLPs) are at the heart of the technology used in the development of Medicago vaccines. Designed to create effective protection against the virus they mimic, they can contribute to the fight against pandemics. They are like a superhero whose mission is to help protect human health around the world.
Antigen-Display technology
Medicago has demonstrated the power of VLPs as their size and structure shows the potential to allow for a broad immune response.
With its Antigen-Display technology, Medicago is developing platforms based on enveloped or capsid VLPs that can incorporate and display antigens designed to target diverse diseases.
This is particularly useful in cases where the target antigen is ineffective without an adjuvant or when the antigenic sequence is a part of a protein that is difficult to produce or formulate.
Moderna said Wednesday the first clinical-trial volunteer received a dose of its Omicron-specific booster shot, code-named mRNA-1273.529.
The Cambridge, Mass., company didn't provide a timetable for when results might be available, but its previous vaccine studies evaluating immune responses have generated preliminary results within about two months.
The start of Moderna's testing, shortly after Pfizer Inc. and BioNTech SE began a similar study, brings vaccine makers and government officials closer to a thorny decision about whether to roll out an Omicron-specific vaccine.
While vaccine-company executives have said they think Omicron-specific boosters will be needed, U.S. government officials have been more cautious, saying current vaccines with boosters might be sufficient to protect against severe disease, even if they don't stop infections.
Also, the current Omicron surge may fade by the time study results are known for the Omicron-specific boosters.
The Omicron variant now spreading around the U.S. and world has mutations that make it less susceptible to immune- system antibodies induced by Moderna's original vaccine, mRNA-1273, also known as Spikevax.
Moderna designed an Omicron-specific vaccine soon after the variant was identified in November.
Since then, Moderna and other researchers have run tests finding that the authorized booster shot of its original vaccine can restore protection against the Omicron strain.
"Nonetheless, given the long-term threat demonstrated by Omicron's immune escape, we are advancing our Omicron- specific variant vaccine booster candidate," said Moderna Chief Executive Stéphane Bancel.
Authorities may determine the Omicron-specific vaccine is warranted if the effectiveness of the original vaccine combined with a booster wanes significantly.
The booster is being tested in an extension of an ongoing middle-stage, or Phase 2, clinical trial that Moderna had previously started to test booster shots. Moderna is conducting the study at 24 locations in the U.S.
In one new portion of the trial, researchers will give a single booster dose of the Omicron-specific vaccine to about 300 adults 18 and older, at least six months after receiving the two-dose primary series of Moderna's original vaccine.
A second group of 300 subjects, who have already received the third dose of Moderna's original vaccine, will receive a booster dose of the Omicron-targeted shot at least three months after getting the original booster dose.
Researchers will track the safety of the Omicron-specific booster shot, and whether it induces immune responses that are likely to be protective against disease caused by the variant.
Separately, a new analysis using blood samples from vaccinated people found that a booster dose of Moderna's vaccine increased neutralizing antibodies against Omicron.
The antibody levels declined, but were still detectable six months after a booster shot, according to the analysis.
The analysis, conducted by researchers from Moderna, the federal government and academic labs, was published online Wednesday by the New England Journal of Medicine.
This version of the coronavirus, which scientists call BA.2, is widely considered stealthier than the original version of Omicron and mRNA vaccine not stopping it. Scientists and health officials around the world are keeping their eyes on a descendant of the Omicron variant that has been found in at least 48 countries, including Australia.
https://stockreport.tips/Bullish-Charts
Medicago’s bid to become the first COVID-19 vaccine maker in Canada to get a product to market for use either as a booster shot or as a first vaccine in places that remain critically unprotected from the disease.
“When we got the results the first reaction was, thank God it works. We were absolutely delighted,” said Brian Ward, Medicago’s medical officer and a professor of medicine and microbiology at McGill University in Montreal. Earlier-stage trials with hundreds of participants suggested the vaccine was safe and that it generated an immune response, but it had to be tested with a much larger group of people in order for researchers to measure its efficacy.
Dr. Ward said the results should not be compared directly with figures released last year by Pfizer-BioNTech and Moderna during the clinical trials for their vaccines. Both showed greater than 90-per-cent efficacy. But those trials were conducted before COVID-19 variants of concern were widespread. The variants have presented vaccines with a somewhat different pathogen than the one they were designed to fight.
“In the variant world, 70 to 75 per cent is a really good vaccine,” Dr. Ward said.
The randomized controlled Phase 3 trial, which got under way in March, involved 24,000 participants. More than two-thirds were located in Brazil and Argentina, and the rest were in the U.S., Mexico, Canada and Britain. Half of those who participated received the Medicago vaccine in two doses separated by 21 days. The other half received a placebo.
Overall, the results showed the vaccine to have 71-per-cent efficacy against all variants that were circulating in the study populations at the time. Its efficacy against the Delta variant, which is currently dominant in Canada, was 75.3 per cent. The efficacy was 88.6 per cent against the Gamma variant. The Omicron variant, now a focus of global concern, had not yet made its appearance when the trial was under way. Information about the vaccine’s efficacy against the new variant may emerge as data continue to accumulate.
Your time of fun is up and MRNA will be rocketing 🚀 back UP and UP in the very near term.
$18b in the bank
$21b in backlog
$32b 2022 est. revenue
$20b 2022 EBIT
$93 EOY Per Share Cash on Hand
Forward PE 3
variant. But getting a booster pumps the protection back up just a little again, new research suggests.
https://www.youtube.com/watch?v=7piZ1wrugqghttps://www.youtube.com/watch?v=7piZ1wrugqg
Antigen-Display technology
Medicago has demonstrated the power of VLPs as their size and structure shows the potential to allow for a broad immune response.
With its Antigen-Display technology, Medicago is developing platforms based on enveloped or capsid VLPs that can incorporate and display antigens designed to target diverse diseases.
This is particularly useful in cases where the target antigen is ineffective without an adjuvant or when the antigenic sequence is a part of a protein that is difficult to produce or formulate.